The upward revision in Gland Pharma’s consensus price target from ₹1678 to ₹1774 is primarily driven by a marked increase in forecast revenue growth, while profit margins remain stable.
What's in the News
- Brookfield and EQT are in advanced talks to acquire Gland Pharma from Fosun Group, with CVC Capital and Warburg Pincus also showing interest; soaring share prices and valuation remain potential deal blockers.
- Gland Pharma received USFDA approval as First-to-File for Angiotensin II Acetate Injection, securing 180-day generic exclusivity for a USD 58 million US market.
- USFDA also approved Gland Pharma as First-to-File for Latanoprostene Bunod Ophthalmic Solution, granting 180-day exclusivity for a USD 171 million US market.
- Gland Pharma’s board approved a grant of 15,347 employee stock options to one employee under its 2025 scheme.
- The board recommended an annual dividend of INR 18 per share payable in September 2025.
Valuation Changes
Summary of Valuation Changes for Gland Pharma
- The Consensus Analyst Price Target has risen from ₹1678 to ₹1774.
- The Consensus Revenue Growth forecasts for Gland Pharma has significantly risen from 10.7% per annum to 13.0% per annum.
- The Net Profit Margin for Gland Pharma remained effectively unchanged, moving only marginally from 17.65% to 17.34%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.